CMP Development, LLC
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients (NCT06021860) | CMP Development, LLC | 2024-06-01 |
| Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug) (NCT03909529) | CMP Development, LLC | 2019-03-10 |
Track CMP Development, LLC automatically
Every clearance here is in the API, with alerts when new ones post.